Fresenius SE & Co KGaA (FRE) PT Set at €62.00 by Independent Research

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €62.00 ($72.09) price objective by stock analysts at Independent Research in a research note issued to investors on Wednesday. The firm currently has a “neutral” rating on the stock. Independent Research’s price target suggests a potential upside of 9.58% from the stock’s current price.

Several other research analysts have also issued reports on FRE. Sanford C. Bernstein set a €83.00 ($96.51) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Tuesday, July 3rd. Morgan Stanley set a €77.00 ($89.53) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Tuesday, July 3rd. Nord/LB set a €82.00 ($95.35) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Friday, July 6th. Bank of America set a €75.00 ($87.21) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Tuesday, July 10th. Finally, Deutsche Bank set a €84.00 ($97.67) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Wednesday, July 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of €75.94 ($88.31).

FRA:FRE opened at €56.58 ($65.79) on Wednesday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: How accurate is the Rule of 72?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply